Literature DB >> 17106430

Cochlear function in facioscapulohumeral muscular dystrophy.

Dimitrios G Balatsouras1, Stavros Korres, Panayota Manta, Angeliki Panousopoulou, Dimitrios Vassilopoulos.   

Abstract

OBJECTIVE: Facioscapulohumeral muscular dystrophy (FSHD) is commonly associated with high-frequency hearing impairment. Our objective was to evaluate a group of normally hearing patients with FSHD using otoacoustic emissions. STUDY
DESIGN: Prospective, randomized clinical trial.
SETTING: A tertiary University-based referral center in Athens, Greece. PATIENTS: The study group consisted of a consecutive sample of 24 patients diagnosed on clinical, histopathologic, and genetic grounds as having FSHD. All subjects were selected on the basis of normal to near normal audiometric pure tone thresholds. Controls consisted of 40 age-matched healthy volunteers.
INTERVENTIONS: Transiently evoked otoacoustic emissions were performed. Whole reproducibility and total response were measured, as well as partial scores at the octave bands centered at 1, 2, 3, 4, and 5 kHz. MAIN OUTCOME MEASURES: Transiently evoked otoacoustic emission measurements were compared between the two groups.
RESULTS: The audiometric findings were normal to near normal for both groups. Compared with controls, most patients had diminished scores in both whole and partial reproducibility scores and overall and partial response scores.
CONCLUSION: Despite normal hearing, subclinical involvement of the cochlea is quite common in patients with FSHD. Our findings support the genetic homogeneity of this disorder and its association with cochlear damage. Otoacoustic emissions might provide a useful tool in the clinical workup and follow-up of these patients.

Entities:  

Mesh:

Year:  2007        PMID: 17106430     DOI: 10.1097/01.mao.0000244362.39696.c8

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  4 in total

Review 1.  Deciphering transcription dysregulation in FSH muscular dystrophy.

Authors:  Melanie Ehrlich; Michelle Lacey
Journal:  J Hum Genet       Date:  2012-06-21       Impact factor: 3.172

Review 2.  Promising Perspective to Facioscapulohumeral Muscular Dystrophy Treatment: Nutraceuticals and Phytochemicals.

Authors:  Ceren Hangül; Sibel Berker Karaüzüm; Esra Küpeli Akkol; Devrim Demir-Dora; Zafer Çetin; Eyüp İlker Saygılı; Gökhan Evcili; Eduardo Sobarzo-Sánchez
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

3.  Characterization of individuals with selected muscular dystrophies from the expanded pilot of the Muscular Dystrophy Surveillance, Tracking and Research Network (MD STARnet) in the United States.

Authors:  Bailey Wallace; K Tiffany Smith; Shiny Thomas; Kristin M Conway; Christina Westfield; Jennifer G Andrews; Richard O Weinert; Thuy Quynh N Do; Natalie Street
Journal:  Birth Defects Res       Date:  2020-07-24       Impact factor: 2.661

4.  Orofacial Muscle Weakening in Facioscapulohumeral Muscular Dystrophy (FSHD) Patients.

Authors:  Dimitrios Konstantonis; Kyriaki Kekou; Petros Papaefthymiou; Heleni Vastardis; Nikoleta Konstantoni; Maria Athanasiou; Maria Svingou; Anastasia Margariti; Angeliki Panousopoulou
Journal:  Children (Basel)       Date:  2022-01-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.